# Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

> **NCT01427946** · PHASE1,PHASE2 · COMPLETED · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** IPI-504
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01427946
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2014-06
- **Final completion:** 2014-10
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01427946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01427946, "Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01427946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*